Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 14/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MAST3 | O60307 | 4/20 | 0.36 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822757 | 0.81 | SYK (0.47) | MAPK8SYKLCKJAK3MAPKAPK5 | |
| SCHEMBL26184439 | 0.79 | MAPK8 (0.38) | MAPK8SYKMAST3MAPKAPK5IKBKB | |
| SCHEMBL25823859 | 0.79 | MAPK8 (0.40) | MAPK8SYKMAST3MAPKAPK5 | |
| SCHEMBL25823409 | 0.78 | MAPKAPK5 (0.43) | MAPK8SYKLCKMAPKAPK5IKBKB | |
| SCHEMBL25822697 | 0.75 | SYK (0.53) | MAPK8SYKLCKMAPKAPK5 | |
| SCHEMBL25823831 | 0.73 | SYK (0.49) | SYK | |
| SCHEMBL21949418 | 0.68 | IRAK4 (0.43) | IRAK4 | |
| SCHEMBL21949415 | 0.68 | PYGM (0.43) | IRAK4 | |
| SCHEMBL15552071 | 0.67 | SYK (0.60) | SYKLCKJAK3 | |
| SCHEMBL25822712 | 0.66 | MAPT (0.58) | SYKMAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | SYK, KDR, FLT1 | MAPK8 637/4885SYK 1/4885IRAK4 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.